Revenues (Tables)

9 Months Ended

Sep. 30, 2022

Revenues were as follows (in millions):


	Three months ended September 30,
	2022						2021
	U.S.		ROW		Total		U.S.		ROW		Total
ENBREL	$	1,086	$	20	$	1,106	$	1,263	$	26	$	1,289
Prolia	590		272		862		530		273		803
Otezla	529		98		627		495		114		609
XGEVA	363		132		495		372		145		517
Aranesp	128		230		358		149		247		396
Repatha	142		167		309		139		133		272
KYPROLIS	217		101		318		198		95		293
Neulasta	205		42		247		360		55		415
Nplate	162		126		288		156		117		273
Other products(1)	1,044		583		1,627		896		557		1,453
Total product sales(2)	$	4,466	$	1,771	6,237		$	4,558	$	1,762	6,320
Other revenues					415						386
Total revenues					$	6,652					$	6,706

	Nine months ended September 30,
	2022						2021
	U.S.		ROW		Total		U.S.		ROW		Total
ENBREL	$	2,965	$	54	$	3,019	$	3,270	$	87	$	3,357
Prolia	1,783		853		2,636		1,569		806		2,375
Otezla	1,366		306		1,672		1,284		335		1,619
XGEVA	1,122		408		1,530		1,061		412		1,473
Aranesp	397		676		1,073		409		709		1,118
Repatha	461		502		963		421		423		844
KYPROLIS	626		296		922		547		277		824
Neulasta	772		133		905		1,215		168		1,383
Nplate	474		364		838		404		341		745
Other products(1)	2,983		1,708		4,691		2,655		1,633		4,288
Total product sales(2)	$	12,949	$	5,300	18,249		$	12,835	$	5,191	18,026
Other revenues					1,235						1,107
Total revenues					$	19,484					$	19,133

____________

(1) Consists of product sales of our non-principal products, as well as our Gensenta and Bergamo subsidiaries.

(2) Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2022 and 2021.